{ "format" : "linked-data-api", "version" : "0.2", "result" : {"_about" : "http://eldaddp.azurewebsites.net/answeredquestions.text?answer.groupedQuestionUIN=99838", "definition" : "http://eldaddp.azurewebsites.net/meta/answeredquestions.text?answer.groupedQuestionUIN=99838", "extendedMetadataVersion" : "http://eldaddp.azurewebsites.net/answeredquestions.text?answer.groupedQuestionUIN=99838&_metadata=all", "first" : "http://eldaddp.azurewebsites.net/answeredquestions.text?_page=0&answer.groupedQuestionUIN=99838", "hasPart" : "http://eldaddp.azurewebsites.net/answeredquestions.text?answer.groupedQuestionUIN=99838", "isPartOf" : "http://eldaddp.azurewebsites.net/answeredquestions.text?answer.groupedQuestionUIN=99838", "items" : [{"_about" : "http://data.parliament.uk/resources/1546762", "AnsweringBody" : [{"_value" : "Department of Health and Social Care"} ], "answer" : {"_about" : "http://data.parliament.uk/resources/1546762/answer", "answerText" : {"_value" : "
As part of the consultation process undertaken in 2020 and 2022, we updated the Branded medicines: statutory scheme. Impact assessments were conducted to understand the drivers of changes to measured sales in the voluntary scheme for branded medicines pricing and access (VPAS).<\/p>
<\/p>
The 2020 and 2022 assessments are available at the following links:<\/p>
<\/p>